Grid Therapeutics
Durham
About Grid Therapeutics
Grid Therapeutics is a biotech company based on the innovative science first developed by Edward F. Patz, Jr. MD and his team of scientists at Duke University Medical Center. Located in Durham, North Carolina, Grid is developing the first human derived targeted immunotherapy for cancer. The antibody was discovered in exceptional outcome early stage lung cancer patients and was isolated from patient’s B-cells using state of the art molecular genomic techniques. “GT103”, the company’s lead asset, is expected to enter a first-in-man Phase 1 clinical trial in advanced-stage solid tumor patients in early 2019.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $5.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Mar 2018)
- Website: gridtherapeutics.com
- Phone: +1 919 987 7190
Industries & Categories
Biotechnology, Life Science, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/grid-therapeutics-26680 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.